K-RAS anticorps (N-Term)
Aperçu rapide pour K-RAS anticorps (N-Term) (ABIN634246)
Antigène
Voir toutes K-RAS (KRAS) AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- N-Term
-
Specificité
- KRAS antibody was raised against the N terminal of KRAS
-
Purification
- Affinity purified
-
Immunogène
- KRAS antibody was raised using the N terminal of KRAS corresponding to a region with amino acids TEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETC
-
-
-
-
Indications d'application
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
KRAS Blocking Peptide, (ABIN5614396), is also available for use as a blocking control in assays to test for specificity of this KRAS antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of KRAS antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- K-RAS (KRAS) (GTPase Kras (KRAS))
-
Autre désignation
- KRAS
-
Sujet
- KRAS is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma.
-
Poids moléculaire
- 22 kDa (MW of target protein)
Antigène
-